Regarding anemia rates at one month, 18.4% (7/38) of patients in the conventional treatment group remained anemic (Hb <11 g/dL), whereas none of the patients (0/53) in the FDI group were anemic statistically significant difference (p<0.01). This evidence concerns the gene GSTM1 and anemia.